Skip to main content
SpringerLink
Log in

Do drugs that target mTOR generate CCN2-mediated fibrogenic side effects?

  • BITS AND BYTES
  • Published:
Journal of Cell Communication and Signaling Aims and scope

Abstract

mTOR, the target of rapamycin, has been promoted as a potential target for cancers, transplantations and even lung fibrosis. However, paradoxically, targeting mTOR has been reported to result in profibrotic side effects. Some recent publications highlight why this might be.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  • Granata S, Santoro G, Masola V, Tomei P, Sallustio F, Pontrelli P, Accetturo M, Antonucci N, Carratù P, Lupo A, Zaza G (2018) In vitro identification of new transcriptomic and miRNomic profiles associated with pulmonary fibrosis induced by high doses everolimus: looking for new Pathogenetic markers and therapeutic targets. Int J Mol Sci 19:pii: E125

    Article  CAS  Google Scholar 

  • Lukey PT, Harrison SA, Yang S, Man Y, Holman BF, Rashidnasab A, Azzopardi G, Grayer M, Simpson JK, Bareille P, Paul L, Woodcock HV, Toshner R, Saunders P, Molyneaux PL, Thielemans K, Wilson FJ, Mercer PF, Chambers RC, Groves AM, Fahy WA, Marshall RP, Maher TM (2019) A randomised, placebo-controlled study of omipalisib (PI3K/mTOR) in idiopathic pulmonary fibrosis. Eur Respir J 53(3) pii: 1801992

  • Malouf MA, Hopkins P, Snell G, Glanville AR (2011) Everolimus in IPF study investigators. An investigator-driven study of everolimus in surgical lung biopsy confirmed idiopathic pulmonary fibrosis. Respirology 16(5):776–783

    Article  PubMed  Google Scholar 

  • Tomei P, Masola V, Granata S, Bellin G, Carratù P, Ficial M, Ventura VA, Onisto M, Resta O, Gambaro G et al (2016) Everolimus-induced epithelial to mesenchymal transition (EMT) in bronchial/pulmonary cells: when the dosage does matter in transplantation. J Nephrol 29:881–891

    Article  CAS  PubMed  Google Scholar 

  • Woodcock HV, Eley JD, Guillotin D, Platé M, Nanthakumar CB, Martufi M, Peace S, Joberty G, Poeckel D, Good RB, Taylor AR, Zinn N, Redding M, Forty EJ, Hynds RE, Swanton C, Karsdal M, Maher TM, Bergamini G, Marshall RP, Blanchard AD, Mercer PF, Chambers RC (2019) The mTORC1/4E-BP1 axis represents a critical signaling node during fibrogenesis. Nat Commun 10:6

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dentistry, Western University, Dental Sciences Building, London, ON, N6A 5C1, Canada

    Andrew Leask

Authors
  1. Andrew Leask
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrew Leask.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Leask, A. Do drugs that target mTOR generate CCN2-mediated fibrogenic side effects?. J. Cell Commun. Signal. 13, 277–278 (2019). https://doi.org/10.1007/s12079-019-00520-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12079-019-00520-y

Keywords

Search

Navigation